CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02192970
NCT02192970Phase 2Completed
CompareCT.gov

Bevacizumab Against Recurrent Retinal Detachment

University of Wisconsin, Madison·interventional·Posted Jul 17, 2014·Updated Mar 26, 2021

In Brief

A Phase 2 clinical trial evaluating Bevacizumab for Retinal Detachment and Proliferative Vitreoretinopathy. Completed, enrolled 101 participants across 1 site.

Detailed Summary

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Detachment, Proliferative Vitreoretinopathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 17, 2014
Enrollment StartJan 21, 2015
Primary CompletionNov 11, 2019
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.0 years ago

Interventions

Bevacizumabdrug